|
|
Analysis of serum ferritin level in aplastic anemia patients and nonaplastic anemia with pancytopenia |
CHENG Yuan-shan1 KUANG Li-ping2 LI Hui-jun1,3 |
1.Department of Hematology,the First Affiliated Hospital of Shantou University Medical College in Guangdong Province, Shantou 515041,China;
2.Department of Pathology,Shantou Central Hospital in Guangdong Province,Shantou 515041, China;
3.Department of Hematology,the University of Hong Kong-Shenzhen Hospital in Guangdong Province,Shenzhen 518053,China |
|
|
Abstract ObjectiveTo investigate the level of serum ferritin (SF)and its clinical significance in newly diagnosed aplastic anemia(AA)and other disorders with pancytopenia.MethodsFrom January 2010 to February 2016,340 patients with pancytopenia treated in our hospital were divided into AA group(176 cases),MDS group(56 cases),leukemia group (57 cases),immune disorders group(36 cases)and megaloblastic anemia group(15 cases)based on their diagnoses.Control group including 30 healthy people received:health examination in our hospital.Serum ferritin level determined by chemiluminescence as well as complete blood count were tested among the patients and control group.ResultsSF level of newly diagnosed AA patients was(536.32±345.29)μg/L,and it was higher than that of control group and immune disorders group and megaloblastic anemia group,but it was lower than that of leukemia group and MDS group.All the differences are statistically significant(P<0.05).In AA group,the patients that older than 60,male patients and sever aplastic anemia (SAA)patients had a higher level of SF.White blood cell count and platelet count were negatively correlated with SF level(r=-0.171,P<0.05;r=-0.156,P<0.05).Iron overload was diagnosed in 13%newly diagnosed AA patients,male and age>60 years old were the risk factors of iron overload (P<0.05).ConclusionSF level of newly diagnosed AA patients is higher than healthy people,and it is lower than patients with leukemia and MDS.SF level has a certain clinical significance to the differential diagnosis of the disorders with pancytopenia.
|
|
|
|
|
[1] |
马茉莉.再生障碍性贫血患者长期多次输血致铁过载对骨髓造血功能抑制的研究[J].中国临床实用医学,2015,(6):56-57.
|
[2] |
张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:6-55.
|
[3] |
中华医学会血液学分会,中国医师协会血液科医师分会.铁过载诊断与治疗的中国专家共识[J].中华血液学杂志,2011,32(8):572-574.
|
[4] |
金朋,施均,李星鑫,等.再生障碍性贫血患者铁代谢异常及铁过载状况研究[J].中华血液学杂志,2013,34(10):877-882
|
[5] |
叶蕾,井丽萍,彭广新,等.治疗前铁过载对急性重型再生障碍性贫血免疫抑制治疗血液学反应的影响[J].中华血液学杂志,2016,37(4):324-328.
|
[6] |
Nahon P,Ganne-Carrié N,Trinchet JC,et al.Hepatic iron overload and risk of hepatocellular carcinoma in cirrhosis[J]. Gastroenterol Clin Biol,2010,34(1):1-7.
|
[7] |
Kew MC.Hepatic iron overload and hepatocellular carcinoma[J].Liver Cancer,2014,3(1):31-40.
|
[8] |
Kikuchi S,Kobune M,Iyama S,et al.Improvement of ironmediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox[J].Free Radic Biol Med,2012,53(4):643-648.
|
[9] |
Weinberg ED.Iron availability and infection[J].Biochim Biophys Acta,2009,1790(7):600-605.
|
[10] |
Guariglia R,Martorelli MC,Villani O,et al.Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy:a brief review[J].Leuk Res,2011,35(5):566-570.
|
[11] |
Lee JW.Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia:a review of experience in South Korea[J].Int J Hematol,2008,88(1):16-23.
|
[12] |
肖志坚.重视骨髓增生异常综合征铁过载的诊断和治疗[J].中华血液学杂志,2011,32(8):505-506
|
[13] |
施均,常红,张莉,等.地拉罗司对伴有铁过载的再生障碍性贫血患者的祛铁疗效及安全性——一项单臂、多中心、前瞻性临床研究[J].中华血液学杂志,2016,37(1):1-6.
|
[14] |
林晓燕,金宏伟,林永志,等.MCM、RDW、LDH和SF联合检测对骨髓增生异常综合征与巨幼细胞性贫血鉴别诊断的临床意义[J].齐齐哈尔医学院学报,2010,31(11):1698-1699.
|
[15] |
杨祯玲.血清维生素B12和铁蛋白检测在贫血诊断和鉴别诊断中的临床价值[J].白求恩医学杂志,2015,13(2):97-98.
|
|
|
|